CAR T-Cell Therapeutics: Alan Leong Of BioWatch Looks Beyond The Buzz For Solid Early-Stage Plays

Alan Leong, senior analyst with BioWatch, tells us about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.